{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:57Z","timestamp":1792788057156,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20180524"],"award-info":[{"award-number":["20180524"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20170367"],"award-info":[{"award-number":["20170367"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hj\u00e4rtat foundation at Danderyds hospital"},{"name":"Gunnar & Ingmar Jungner Foundation of Laboratory Medicine"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dysglycaemia is associated with overall cardiovascular disease even at prediabetes levels. The aim of this study was to explore the association between glucose levels and future risk of developing atrial fibrillation and heart failure, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective cohort study subjects from the Swedish AMORIS-cohort with fasting glucose from health examinations 1985\u20131996 without previous cardiovascular disease (N\u2009=\u2009294,057) were followed to 31 December 2011 for incident atrial fibrillation or heart failure. Cox proportional hazard models with attained age as timescale and adjustments for sex, cholesterol, triglycerides, and socioeconomic status were used to estimate hazard ratios by glucose categorized groups (normal glucose 3.9\u20136.0\u00a0mmol\/L, impaired fasting glucose; 6.1\u20136.9\u00a0mmol\/L, undiagnosed diabetes\u2009\u2265\u20097.0\u00a0mmol\/L, and diagnosed diabetes).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a mean follow-up time of 19.1\u00a0years 28,233 individuals developed atrial fibrillation and 25,604 developed heart failure. The HR for atrial fibrillation was 1.19 (95% confidence interval 1.13\u20131.26) for impaired fasting glucose, 1.23 (1.15\u20131.32) for undiagnosed diabetes and 1.30 (1.21\u20131.41) for diagnosed diabetes. Corresponding figures for heart failure were; 1.40 (1.33\u20131.48), 2.11 (1.99\u20132.23), 2.22 (2.08\u20132.36) respectively. In a subset with BMI data (19%), these associations were attenuated and for atrial fibrillation only remained statistically significant among subjects with diagnosed diabetes (HR 1.25; 1.02\u20131.53).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Fasting glucose at prediabetes levels is associated with development of atrial fibrillation and heart failure. To some extent increased BMI may drive this association.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-021-01422-3","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T10:02:51Z","timestamp":1637748171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6123-3591","authenticated-orcid":false,"given":"Viktor","family":"Lind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Hammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Lundman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Talb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Walldius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"7","key":"1422_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633\u201344.","journal-title":"N Engl J Med"},{"key":"1422_CR2","doi-asserted-by":"crossref","unstructured":"The Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215\u201322.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"1422_CR3","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 9th edn. 2019. https:\/\/diabetesatlas.org\/atlas\/ninth-edition\/. Accessed 30 Apr 2020."},{"issue":"10","key":"1422_CR4","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","volume":"132","author":"MA Cavender","year":"2015","unstructured":"Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Circulation. 2015;132(10):923\u201331.","journal-title":"Circulation"},{"issue":"8","key":"1422_CR5","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s00125-016-3971-y","volume":"59","author":"A Norhammar","year":"2016","unstructured":"Norhammar A, Bodeg\u00e5rd J, Nystr\u00f6m T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006\u20132013. Diabetologia. 2016;59(8):1692\u2013701.","journal-title":"Diabetologia"},{"issue":"1","key":"1422_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12933-021-01313-7","volume":"20","author":"A Groenewegen","year":"2021","unstructured":"Groenewegen A, Zwartkruis VW, Cekic B, de Boer RA, Rienstra M, Hoes AW, et al. Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes. Cardiovasc Diabetol. 2021;20(1):123.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1422_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","volume":"74","author":"A Wang","year":"2019","unstructured":"Wang A, Green JB, Halperin JL, Piccini JP. Atrial fibrillation and diabetes mellitus. J Am Coll Cardiol. 2019;74(8):1107\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1422_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","volume":"271","author":"EJ Benjamin","year":"1994","unstructured":"Benjamin EJ, Levy D, Vaziri SM, D\u2019Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840\u20134.","journal-title":"JAMA"},{"issue":"1","key":"1422_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1479164117735013","volume":"15","author":"S Karayiannides","year":"2018","unstructured":"Karayiannides S, Lundman P, Friberg L, Norhammar A. High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: a nationwide report. Diabetes Vasc Dis Res. 2018;15(1):31\u20138.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"8","key":"1422_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jacep.2019.05.018","volume":"5","author":"E Donnellan","year":"2019","unstructured":"Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, et al. Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation. JACC Clin Electrophysiol. 2019;5(8):897\u2013903.","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"1422_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.numecd.2018.07.005","volume":"28","author":"D Aune","year":"2018","unstructured":"Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, et al. Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2018;28(11):1081\u201391.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"1422_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.atherosclerosis.2009.10.042","volume":"210","author":"J Wang","year":"2010","unstructured":"Wang J, Sarnola K, Ruotsalainen S, Moilanen L, Lepist\u00f6 P, Laakso M, et al. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly finns. Atherosclerosis. 2010;210(1):237\u201342.","journal-title":"Atherosclerosis"},{"issue":"5","key":"1422_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ahj.2013.08.012","volume":"166","author":"R Latini","year":"2013","unstructured":"Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, et al. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Am Heart J. 2013;166(5):935\u201340.","journal-title":"Am Heart J"},{"issue":"10","key":"1422_CR14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1161\/CIRCULATIONAHA.107.744466","volume":"117","author":"H Watanabe","year":"2008","unstructured":"Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117(10):1255\u201360.","journal-title":"Circulation"},{"issue":"14","key":"1422_CR15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCULATIONAHA.110.009035","volume":"123","author":"RR Huxley","year":"2011","unstructured":"Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors. Circulation. 2011;123(14):1501\u20138.","journal-title":"Circulation"},{"issue":"5","key":"1422_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jdiacomp.2018.02.004","volume":"32","author":"D Aune","year":"2018","unstructured":"Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32(5):501\u201311.","journal-title":"J Diabetes Complications"},{"issue":"4","key":"1422_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/ije\/dyw333","volume":"46","author":"G Walldius","year":"2017","unstructured":"Walldius G, Malmstr\u00f6m H, Jungner I, de Faire U, Lambe M, Van HM, et al. Cohort profile: the AMORIS cohort. Int J Epidemiol. 2017;46(4):1103\u20131103i.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"1422_CR18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/dom.13241","volume":"20","author":"H Malmstr\u00f6m","year":"2018","unstructured":"Malmstr\u00f6m H, Walldius G, Carlsson S, Grill V, Jungner I, Gudbj\u00f6rnsdottir S, et al. Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: experience from the AMORIS study. Diabetes Obes Metab. 2018;20(6):1419\u201326.","journal-title":"Diabetes Obes Metab"},{"key":"1422_CR19","unstructured":"World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO\/IDF consultation 2006. https:\/\/www.who.int\/diabetes\/publications\/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 30 Apr 2020."},{"issue":"9","key":"1422_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1422_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2337\/diacare.22.2.233","volume":"22","author":"M Coutinho","year":"1999","unstructured":"Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233\u201340.","journal-title":"Diabetes Care"},{"issue":"2","key":"1422_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/ejhf.1646","volume":"22","author":"M Packer","year":"2020","unstructured":"Packer M. Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. Eur J Heart Fail. 2020;22(2):214\u201327.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1422_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Bax JJ, Boriani G, Dan GA, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373\u2013498.","journal-title":"Eur Heart J"},{"key":"1422_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yjmcc.2015.12.011","volume":"90","author":"I Russo","year":"2016","unstructured":"Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84\u201393.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"1422_CR25","doi-asserted-by":"publisher","first-page":"e014609","DOI":"10.1161\/JAHA.119.014609","volume":"9","author":"M Singh","year":"2020","unstructured":"Singh M, Sethi A, Mishra AK, Subrayappa NK, Stapleton DD, Pellikka PA. Echocardiographic imaging challenges in obesity: guideline recommendations and limitations of adjusting to body size. J Am Heart Assoc. 2020;9(2):e014609.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"1422_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.acvd.2015.01.009","volume":"108","author":"M Tadic","year":"2015","unstructured":"Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Arch Cardiovasc Dis. 2015;108(4):269\u201376.","journal-title":"Arch Cardiovasc Dis"},{"issue":"8","key":"1422_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00392-013-0566-1","volume":"102","author":"M Greif","year":"2013","unstructured":"Greif M, Von ZF, Wakili R, Tittus J, Becker C, Helbig S, et al. Increased pericardial adipose tissue is correlated with atrial fibrillation and left atrial dilatation. Clin Res Cardiol. 2013;102(8):555\u201362.","journal-title":"Clin Res Cardiol"},{"issue":"27","key":"1422_CR28","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","volume":"36","author":"PM Seferovi\u0107","year":"2015","unstructured":"Seferovi\u0107 PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718\u201327.","journal-title":"Eur Heart J"},{"issue":"21","key":"1422_CR29","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.jacc.2014.09.028","volume":"64","author":"RK Pathak","year":"2014","unstructured":"Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64(21):2222\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1422_CR30","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","volume":"65","author":"RK Pathak","year":"2015","unstructured":"Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort. J Am Coll Cardiol. 2015;65(20):2159\u201369.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1422_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227\u201334.","journal-title":"Circulation"},{"issue":"1","key":"1422_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-021-01285-8","volume":"20","author":"YH Chan","year":"2021","unstructured":"Chan YH, Chen SW, Chao TF, Kao YW, Huang CY, Chu PH. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium\u2013glucose cotransporter 2 inhibitor. Cardiovasc Diabetol. 2021;20(1):93.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1422_CR33","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.hrthm.2015.06.038","volume":"12","author":"R Hajhosseiny","year":"2015","unstructured":"Hajhosseiny R, Matthews GK, Lip GYH. Metabolic syndrome, atrial fibrillation, and stroke: tackling an emerging epidemic. Heart Rhythm. 2015;12(11):2332\u201343.","journal-title":"Heart Rhythm"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01422-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T10:03:18Z","timestamp":1637748198000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01422-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1422"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01422-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Declaration of Helsinki and was approved by the Regional Ethical Review Board in Stockholm (Reg.No. 2010\/1047-31\/1). No written consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest concerning this article. VL has nothing to disclose. NH has nothing to disclose. PL reports personal fees from Boehringer Ingelheim, personal fees from Sanofi, personal fees from Novo Nordisk, outside the submitted work. LF reports personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from BMS, personal fees from Pfizer, personal fees from Sanofi, outside the submitted work. MT has nothing to disclose. GW has nothing to disclose. AN reports personal fees from Astra Zeneca, personal fees from MSD, personal fees from Boehringer Ingelheim, personal fees from Lilly, personal fees from Novo Nordisk, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}